FAFÍLEK, Bohumil, Marek HAMPL, Nikola ŘIČÁNKOVÁ, I. VESELA, Lukáš BÁLEK, Michaela BOSÁKOVÁ, Iva GUDERNOVÁ, Miroslav VAŘECHA, marcela BUCHTOVÁ and Pavel KREJČÍ. Statins do not inhibit the FGFR signaling in chondrocytes. Osteoarthritis and Cartilage. Oxford: Elsevier Science Inc., 2017, vol. 25, No 9, p. 1522-1530. ISSN 1063-4584. Available from: https://dx.doi.org/10.1016/j.joca.2017.05.014.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Statins do not inhibit the FGFR signaling in chondrocytes
Authors FAFÍLEK, Bohumil (203 Czech Republic, belonging to the institution), Marek HAMPL (203 Czech Republic, belonging to the institution), Nikola ŘIČÁNKOVÁ (203 Czech Republic, belonging to the institution), I. VESELA (203 Czech Republic), Lukáš BÁLEK (203 Czech Republic, belonging to the institution), Michaela BOSÁKOVÁ (203 Czech Republic, belonging to the institution), Iva GUDERNOVÁ (203 Czech Republic, belonging to the institution), Miroslav VAŘECHA (203 Czech Republic, belonging to the institution), marcela BUCHTOVÁ (203 Czech Republic, belonging to the institution) and Pavel KREJČÍ (203 Czech Republic, guarantor, belonging to the institution).
Edition Osteoarthritis and Cartilage, Oxford, Elsevier Science Inc. 2017, 1063-4584.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30211 Orthopaedics
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 5.454
RIV identification code RIV/00216224:14110/17:00097411
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.joca.2017.05.014
UT WoS 000407934000019
Keywords in English Achondroplasia; Chondrocytes; FGF signaling; Statins
Tags EL OK, podil
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 13/3/2018 19:26.
Abstract
Objective Statins are widely used drugs for cholesterol lowering, which were recently found to counteract the effects of aberrant fibroblast growth factor receptor (FGFR3) signaling in cell and animal models of FGFR3-related chondrodysplasia. This opened an intriguing therapeutic possibility for human dwarfing conditions caused by gain-of-function mutations in FGFR3, although the mechanism of statin action on FGFR3 remains unclear. Here, we determine the effect of statins on FGFR signaling in chondrocytes. Design Cultured chondrocyte cell lines, mouse embryonic tibia cultures and limb bud micromasses were treated with FGF2 to activate FGFR signaling. The effects of atorvastatin, fluvastatin, lovastatin and pravastatin on FGFR3 protein stability and on FGFR-mediated chondrocyte growth-arrest, loss of extracellular matrix (ECM), induction of premature senescence and hypertrophic differentiation were evaluated. Results Statins did not alter the level of FGFR3 protein expression nor produce any effect on FGFR-mediated inhibition of chondrocyte proliferation and hypertrophic differentiation in cultured chondrocyte cell lines, mouse tibia cultures or limb bud micromasses. Conclusion We conclude that statins do not inhibit the FGFR signaling in chondrocytes. Therefore the statin-mediated rescue of FGFR3-related chondrodysplasia, described before, is likely not intrinsic to the growth plate cartilage.
Links
LH12004, research and development projectName: FGFR3-specifický adaptérom a jeho role v patologické FGFR3 signalizaci v nemoci (Acronym: AMVIS-FGFR3)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/0810/2016, interní kód MUName: Molekulární a buněčná biologie
Investor: Masaryk University, Category A
PrintDisplayed: 16/7/2024 23:33